|
|
Babraham Research Campus
Cambridge, CB22 3AT United Kingdom
phone:(44) (0) 1223 496787
fax:(44) (0) 1223 496788
|
|
| Symbol |
Private |
| Exchange |
|
| Founded |
0 |
| Employees |
|
|
|
| www.zyentia.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Therapeutics to treat amyloid diseases including Alzheimer's disease, Parkinson's disease, and diabetes. |
|
| Management |
| Jess Zurdo, PhD, Research Director & Interim Chief Executive; David Glover, MRCP FFPM, Non-Executive Chairman; Jeffrey S. Garner, Non-Executive Director; Joy Duffen, MA.Vet.MB., PhD, MRVCS, DIBT, IMC, Non-Executive Director; Bart Wuurman, Drs, Non-Executive Director; Chris Dobson, PhD, FRS, Founder and Scientific Advisor |
| |
|
|
| |
|
| Keywords |
| protein, misfolding, disease, peptide, alzheimer's parkinson's, trigger, oligomers |
|
|
|
| Description |
|
Zyentia Limited is a company operating in the fields of protein misfolding and human disease. Zyentia's main focus of interest is on protein conformational diseases, although its portfolio also includes IP from the areas of novel peptide therapeutics and biomaterials |
|
| Products / Services |
Zyentia is developing novel therapeutics for this group of diseases, focusing in the first instance on type 2 diabetes. The Company's developing research capabilities are also centered on identifying therapeutic leads for other amyloid diseases including Alzheimer's disease and Parkinson's disease.
|
|
| Technology / Differentiation |
| Protein aggregation is of aetiological importance in a number of diseases characteristic of aging and may be of central importance to the aging process itself. Diseases caused by protein aggregation (of which amyloid diseases are part) include type 2 diabetes, Alzheimer's and Parkinson's as well as the prionoses, also known as transmissible spongiform encephalopathies. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members